The earnings call conveyed strong growth and strategic developments with significant revenue increases and strategic alliances. However, there were challenges with the VEVYE revenue decline and underperformance in the specialty branded portfolio.

Company Guidance

During Harrow's second quarter 2025 earnings call, the company provided guidance on various financial metrics and strategic goals. Harrow aims to achieve a $250 million revenue quarter by the end of 2027, leveraging its expansive portfolio of over 59 ophthalmic products. The company reported a total revenue of $63.7 million for the second quarter, marking a 30% increase over the same period in 2024 and a 33% rise from the first quarter of 2025. To meet its 2025 guidance of over $280 million, Harrow needs to generate approximately $169 million in revenue in the latter half of the year. The company also highlighted the growth of specific products, with VEVYE seeing a 66% rise in prescription volumes and IHEEZO experiencing a 25% increase in unit volume. Harrow anticipates VEVYE to generate over $100 million in annual revenue, while IHEEZO is projected to surpass $50 million. Adjusted EBITDA for the second quarter was reported at $17 million, with net income at $5 million. Harrow's strategy includes expanding its commercial infrastructure and entering new markets, supported by strategic acquisitions such as the U.S. rights to BYQLOVI and Samsung's ophthalmic biosimilars portfolio.

Strong Revenue Growth

Total revenue for Q2 2025 was $63.7 million, a 30% increase over Q2 2024 and a sequential increase of 33% from Q1 2025.

VEVYE Prescription Growth

VEVYE saw a 66% growth in prescription volumes quarter-over-quarter, driven by the VEVYE Access for All initiative.

Strategic Alliances and Acquisitions

Announced a strategic alliance with Apollo Care and secured U.S. rights to BYQLOVI and Samsung's ophthalmic biosimilars portfolio.

IHEEZO and TRIESENCE Growth

IHEEZO's revenue increased by 251% from Q1 2025 and TRIESENCE achieved 32% quarter-over-quarter growth.

Adjusted EBITDA

Adjusted EBITDA for Q2 2025 was $17 million with $5 million of net income, highlighting operating leverage.

Harrow Health (HROW) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

HROW Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 17, 2025	2025 (Q3)	0.23 / -	-0.12	―	―	―
Aug 11, 2025	2025 (Q2)	<0.01 / 0.13	-0.18	172.22% (+0.31)
May 08, 2025	2025 (Q1)	-0.05 / -0.50	-0.38	-31.58% (-0.12)
Mar 27, 2025	2024 (Q4)	0.08 / 0.24	-0.26	192.31% (+0.50)
Nov 13, 2024	2024 (Q3)	-0.05 / -0.12	-0.13	7.69% (+0.01)
Aug 07, 2024	2024 (Q2)	-0.18 / -0.18	-0.14	-28.57% (-0.04)
May 13, 2024	2024 (Q1)	-0.22 / -0.38	-0.22	-72.73% (-0.16)
Mar 19, 2024	2023 (Q4)	-0.04 / -0.26	0.04	-750.00% (-0.30)
Nov 13, 2023	2023 (Q3)	0.04 / -0.13	-0.24	45.83% (+0.11)
Aug 09, 2023	2023 (Q2)	-0.04 / -0.14	-0.23	39.13% (+0.09)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

HROW Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 11, 2025	$33.74	$34.83	+3.23%
May 08, 2025	$23.59	$24.40	+3.43%
Mar 27, 2025	$27.87	$26.21	-5.96%
Nov 13, 2024	$51.80	$42.86	-17.26%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.